SK Biopharmaceuticals and ProEn Therapeutics Collaborate to Advance Oncology Research and Develop Radiopharmaceuticals

SK Biopharmaceuticals Collaborates with ProEn Therapeutics

In a significant move toward enhancing its oncology research capabilities, SK Biopharmaceuticals has announced a strategic collaboration with ProEn Therapeutics. This partnership aims to advance the development of two preclinical radiopharmaceutical candidates by the year 2027. This initiative is part of SK Biopharmaceuticals' broader objective to solidify its position as a global leader in the field of radiopharmaceutical therapies (RPT).

SK Biopharmaceuticals, renowned for its pioneering work in biotechnology, particularly within central nervous system disorders and oncology, seeks to build a formidable portfolio of innovative treatments. With the increasing demand for effective cancer therapies worldwide, this collaboration comes at a crucial time, promising to provide innovative solutions that target tumors more selectively while minimizing damage to healthy tissues.

The collaboration hinges on the utilization of ProEn Therapeutics' proprietary ArtBody™ platform. This unique bivalent binder technology is designed to identify and bind to specific tumor antigens, facilitating enhanced tumor targeting capabilities. Unlike conventional treatments, the small protein-based radiopharmaceuticals are tailored for better tumor penetration and rapid clearance from the body, potentially leading to improved safety and efficacy profiles.

Il-Han Lee, CEO of ProEn Therapeutics, expressed his enthusiasm for the collaboration, stating, "We are pleased to enter this joint research and are confident that the ArtBody™ platform will synergize with and complement SK Biopharmaceuticals' RPT efforts. Our goal is to deliver outcomes that not only meet the expectations of both companies but most importantly, fulfill the needs of patients."

This partnership represents a continuation of SK Biopharmaceuticals' commitment to expanding its research capabilities through strategic alliances. The company has previously secured additional resources and assets, including a radiopharmaceutical compound under license and an agreement to procure actinium-225, a radioisotope crucial for their therapies. This groundwork forms part of SK Biopharmaceuticals' outlined "RPT Roadmap," aimed at gaining a competitive edge in the ever-evolving field of nuclear medicine.

Donghoon Lee, CEO of SK Biopharmaceuticals, remarked on the significance of this research collaboration: "By leveraging ProEn Therapeutics' platform technology, we aim to overcome limitations existing in current therapies, pushing the boundaries of effective and safer cancer treatments. This endeavor will not only enhance our research capabilities but also affirm our commitment to leading the global RPT research and development landscape."

The ArtBody™ technology provides several advantages over traditional therapies, including greater stability, improved structural robustness, and the ability for mass production using bacteria. This cost-effective aspect is pivotal, as many oncology treatments face challenges related to high manufacturing expenses and potential toxicity. As a result, small proteins are increasingly being recognized as key players in the development of new drugs within both pharma and biotech industries.

In conclusion, this collaboration between SK Biopharmaceuticals and ProEn Therapeutics highlights the growing trend of innovative approaches to cancer treatment through advanced biotechnology. With a clear vision and a focused strategy, both companies are poised to make significant advances in the field of oncology, ultimately aiming to deliver more effective and targeted therapies to patients worldwide. Their combined efforts could well mark a transformative phase in the battle against cancer, bringing hope to millions facing this challenging disease.

By combining expertise, technology, and a shared commitment to patient outcomes, SK Biopharmaceuticals and ProEn Therapeutics are set to embark on a potent journey of discovery and innovation in cancer treatment that could reshape the landscape of oncological care.